{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:28:02Z","timestamp":1794932882805,"version":"4.9.1"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum der Ruhr-Universit\u00e4t Bochum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>\n                    <jats:sc>A<\/jats:sc>\n                    bstract\n                  <\/jats:title>\n                  <jats:p>\n                    Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along with their derivatives they have shown therapeutic success in type 2 diabetes, with the potential for further improvements in glycaemic, cardiorenal and body weight-related outcomes. In type 2 diabetes, the incretin effect (greater insulin secretory response after oral glucose than with \u2018isoglycaemic\u2019 i.v. glucose, i.e. with an identical glycaemic stimulus) is markedly reduced or absent. This appears to be because of a reduced ability of GIP to stimulate insulin secretion, related either to an overall impairment of beta cell function or to specific defects in the GIP signalling pathway. It is likely that a reduced incretin effect impacts on postprandial glycaemic excursions and, thus, may play a role in the deterioration of glycaemic control. In contrast, the insulinotropic potency of GLP-1 appears to be much less impaired, such that exogenous GLP-1 can stimulate insulin secretion, suppress glucagon secretion and reduce plasma glucose concentrations in the fasting and postprandial states. This has led to the development of incretin-based glucose-lowering medications (selective GLP-1 receptor agonists or, more recently, co-agonists, e.g. that stimulate GIP and GLP-1 receptors). Tirzepatide (a GIP\/GLP-1 receptor co-agonist), for example, reduces HbA\n                    <jats:sub>1c<\/jats:sub>\n                    and body weight in individuals with type 2 diabetes more effectively than selective GLP-1 receptor agonists (e.g. semaglutide). The mechanisms by which GIP receptor agonism may contribute to better glycaemic control and weight loss after long-term exposure to tirzepatide are a matter of active research and may change the pessimistic view that developed after the disappointing lack of insulinotropic activity in people with type 2 diabetes when exposed to GIP in short-term experiments. Future medications that stimulate incretin hormone and other receptors simultaneously may have the potential to further increase the ability to control plasma glucose concentrations and induce weight loss.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00125-023-05956-x","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T22:01:26Z","timestamp":1689026486000},"page":"1780-1795","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Incretin hormones and type 2 diabetes"],"prefix":"10.1007","volume":"66","author":[{"given":"Michael A.","family":"Nauck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"5956_CR1","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"5956_CR2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/BF02427280","volume":"29","author":"M Nauck","year":"1986","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46\u201352. https:\/\/doi.org\/10.1007\/BF02427280","journal-title":"Diabetologia"},{"key":"5956_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1210\/jc.2010-2435","volume":"96","author":"JI Bagger","year":"2011","unstructured":"Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsb\u00f8ll T (2011) Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:737\u2013745. https:\/\/doi.org\/10.1210\/jc.2010-2435","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","volume":"4","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Meier JJ (2016) The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 4:525\u2013536. https:\/\/doi.org\/10.1016\/S2213-8587(15)00482-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5956_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/BF00274255","volume":"32","author":"IR Jones","year":"1989","unstructured":"Jones IR, Owens DR, Luzio S, Williams S, Hayes TM (1989) The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 32:668\u2013677. https:\/\/doi.org\/10.1007\/BF00274255","journal-title":"Diabetologia"},{"key":"5956_CR6","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","volume":"50","author":"T Vilsb\u00f8ll","year":"2001","unstructured":"Vilsb\u00f8ll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50:609\u2013613. https:\/\/doi.org\/10.2337\/diabetes.50.3.609","journal-title":"Diabetes"},{"key":"5956_CR7","doi-asserted-by":"publisher","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","volume":"86","author":"MB Toft-Nielsen","year":"2001","unstructured":"Toft-Nielsen MB, Damholt MB, Madsbad S et al (2001) Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717\u20133723. https:\/\/doi.org\/10.1210\/jcem.86.8.7750","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","volume":"56","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ et al (2013) Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56:965\u2013972. https:\/\/doi.org\/10.1007\/s00125-013-2841-0","journal-title":"Diabetologia"},{"key":"5956_CR9","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.2337\/dc13-0465","volume":"36","author":"S Calanna","year":"2013","unstructured":"Calanna S, Christensen M, Holst JJ et al (2013) Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 36:3346\u20133352. https:\/\/doi.org\/10.2337\/dc13-0465","journal-title":"Diabetes Care"},{"key":"5956_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.regpep.2004.06.020","volume":"122","author":"MA Nauck","year":"2004","unstructured":"Nauck MA, El-Ouaghlidi A, Gabrys B et al (2004) Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 122:209\u2013217. https:\/\/doi.org\/10.1016\/j.regpep.2004.06.020","journal-title":"Regul Pept"},{"key":"5956_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/j.1464-5491.2005.01567.x","volume":"22","author":"MN Feinglos","year":"2005","unstructured":"Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O (2005) Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet Med 22:1016\u20131023. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01567.x","journal-title":"Diabetic Med"},{"key":"5956_CR12","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","volume":"28","author":"RA DeFronzo","year":"2005","unstructured":"DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092\u20131100. https:\/\/doi.org\/10.2337\/diacare.28.5.1092","journal-title":"Diabetes Care"},{"key":"5956_CR13","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.2337\/db14-1751","volume":"64","author":"K Faerch","year":"2015","unstructured":"Faerch K, Torekov SS, Vistisen D et al (2015) GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: The ADDITION-PRO Study. Diabetes 64:2513\u20132525. https:\/\/doi.org\/10.2337\/db14-1751","journal-title":"Diabetes"},{"key":"5956_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.2337\/db07-1315","volume":"57","author":"E Muscelli","year":"2008","unstructured":"Muscelli E, Mari A, Casolaro A et al (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57:1340\u20131348. https:\/\/doi.org\/10.2337\/db07-1315","journal-title":"Diabetes"},{"issue":"Suppl. 3","key":"5956_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","volume":"23","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Pfeiffer AFH (2021) The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab 23(Suppl. 3):5\u201329. https:\/\/doi.org\/10.1111\/dom.14496","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR16","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ (2021) Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 42:101\u2013132. https:\/\/doi.org\/10.1210\/endrev\/bnaa032","journal-title":"Endocr Rev"},{"key":"5956_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1210\/endo-99-3-780","volume":"99","author":"RA Pederson","year":"1976","unstructured":"Pederson RA, Brown JC (1976) The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas. Endocrinology 99:780\u2013785. https:\/\/doi.org\/10.1210\/endo-99-3-780","journal-title":"Endocrinology"},{"key":"5956_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1210\/endo-103-2-610","volume":"103","author":"RA Pederson","year":"1978","unstructured":"Pederson RA, Brown JC (1978) Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas. Endocrinology\u00a0103:610\u2013615. https:\/\/doi.org\/10.1210\/endo-103-2-610","journal-title":"Endocrinol"},{"key":"5956_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1210\/jcem-37-5-826","volume":"37","author":"J Dupr\u00e9","year":"1973","unstructured":"Dupr\u00e9 J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826\u2013828. https:\/\/doi.org\/10.1210\/jcem-37-5-826","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/00365528509091657","volume":"20","author":"PF Amland","year":"1985","unstructured":"Amland PF, Jorde R, Aanderud S, Burhol PG, Giercksky KE (1985) Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state. Scand J Gastroenterol 20:315\u2013320. https:\/\/doi.org\/10.3109\/00365528509091657","journal-title":"Scand J Gastroenterol"},{"key":"5956_CR21","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0026-0495(87)90153-3","volume":"36","author":"T Krarup","year":"1987","unstructured":"Krarup T, Saurbrey N, Moody AJ, Kuhl C, Madsbad S (1987) Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus. Metabolism 36:677\u2013682. https:\/\/doi.org\/10.1016\/0026-0495(87)90153-3","journal-title":"Metabolism"},{"issue":"1","key":"5956_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","volume":"91","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Heimesaat MM, \u00d8rskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301\u2013307. https:\/\/doi.org\/10.1172\/JCI116186","journal-title":"J Clin Invest"},{"key":"5956_CR23","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","volume":"45","author":"T Vilsb\u00f8ll","year":"2002","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45:1111\u20131119. https:\/\/doi.org\/10.1007\/s00125-002-0878-6","journal-title":"Diabetologia"},{"key":"5956_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","volume":"52","author":"PV H\u00f8jberg","year":"2009","unstructured":"H\u00f8jberg PV, Vilsb\u00f8ll T, Rabol R et al (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199\u2013207. https:\/\/doi.org\/10.1007\/s00125-008-1195-5","journal-title":"Diabetologia"},{"key":"5956_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","volume":"211","author":"JJ Holst","year":"1987","unstructured":"Holst JJ, \u00d8rskov C, Nielsen OV, Schwartz TW (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169\u2013174. https:\/\/doi.org\/10.1016\/0014-5793(87)81430-8","journal-title":"FEBS Lett"},{"issue":"2","key":"5956_CR26","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1172\/JCI112855","volume":"79","author":"S Mojsov","year":"1987","unstructured":"Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79(2):616\u2013619. https:\/\/doi.org\/10.1172\/JCI112855","journal-title":"J Clin Invest"},{"key":"5956_CR27","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/s0140-6736(87)91194-9","volume":"2","author":"B Kreymann","year":"1987","unstructured":"Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2:1300\u20131304. https:\/\/doi.org\/10.1016\/s0140-6736(87)91194-9","journal-title":"Lancet"},{"key":"5956_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2337\/diab.39.11.1320","volume":"39","author":"S Suzuki","year":"1990","unstructured":"Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K (1990) Reduced insulinotropic effects of glucagonlike peptide I-(7\u201336)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes 39:1320\u20131325. https:\/\/doi.org\/10.2337\/diab.39.11.1320","journal-title":"Diabetes"},{"key":"5956_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, \u00d8rskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7\u201336 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741\u2013744. https:\/\/doi.org\/10.1007\/BF00401145","journal-title":"Diabetologia"},{"key":"5956_CR30","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jcem.86.8.7743","volume":"86","author":"MB Toft-Nielsen","year":"2001","unstructured":"Toft-Nielsen MB, Madsbad S, Holst JJ (2001) Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86:3853\u20133860. https:\/\/doi.org\/10.1210\/jcem.86.8.7743","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR31","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.2337\/diacare.21.11.1925","volume":"21","author":"MA Nauck","year":"1998","unstructured":"Nauck MA, Sauerwald A, Ritzel R, Holst JJ, Schmiegel W (1998) Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. Diabetes Care 21:1925\u20131931. https:\/\/doi.org\/10.2337\/diacare.21.11.1925","journal-title":"Diabetes Care"},{"key":"5956_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/(SICI)1096-9136(1998110)15:11<937::AID-DIA701>3.0.CO;2-0","volume":"15","author":"MA Nauck","year":"1998","unstructured":"Nauck MA, Weber I, Bach I et al (1998) Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients. Diabet Med 15:937\u2013945. https:\/\/doi.org\/10.1002\/(SICI)1096-9136(1998110)15:11%3c937::AID-DIA701%3e3.0.CO;2-0","journal-title":"Diabetic Med"},{"key":"5956_CR33","doi-asserted-by":"publisher","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","volume":"52","author":"LL Kjems","year":"2003","unstructured":"Kjems LL, Holst JJ, V\u00f8lund A, Madsbad S (2003) The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380\u2013386. https:\/\/doi.org\/10.2337\/diabetes.52.2.380","journal-title":"Diabetes"},{"key":"5956_CR34","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00125-003-1103-y","volume":"46","author":"JJ Meier","year":"2003","unstructured":"Meier JJ, Gallwitz B, Siepmann N et al (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46:798\u2013801. https:\/\/doi.org\/10.1007\/s00125-003-1103-y","journal-title":"Diabetologia"},{"key":"5956_CR35","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2337\/db11-0979","volume":"60","author":"M Christensen","year":"2011","unstructured":"Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60:3103\u20133109. https:\/\/doi.org\/10.2337\/db11-0979","journal-title":"Diabetes"},{"key":"5956_CR36","doi-asserted-by":"publisher","first-page":"E 418","DOI":"10.1210\/jc.2013-3644","volume":"99","author":"MB Christensen","year":"2014","unstructured":"Christensen MB, Calanna S, Holst JJ, Vilsboll T, Knop FK (2014) Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 99:E 418-426. https:\/\/doi.org\/10.1210\/jc.2013-3644","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR37","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2337\/db08-0958","volume":"58","author":"CW Chia","year":"2009","unstructured":"Chia CW, Carlson OD, Kim W et al (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342\u20131349. https:\/\/doi.org\/10.2337\/db08-0958","journal-title":"Diabetes"},{"key":"5956_CR38","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1210\/jc.2009-0921","volume":"94","author":"KJ Hare","year":"2009","unstructured":"Hare KJ, Knop FK, Asmar M et al (2009) Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:4679\u20134687. https:\/\/doi.org\/10.1210\/jc.2009-0921","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR39","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"MA Nauck","year":"2002","unstructured":"Nauck MA, Heimesaat MM, Behle K et al (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239\u20131246. https:\/\/doi.org\/10.1210\/jcem.87.3.8355","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR40","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2337\/db09-1414","volume":"59","author":"KJ Hare","year":"2010","unstructured":"Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765\u20131770. https:\/\/doi.org\/10.2337\/db09-1414","journal-title":"Diabetes"},{"key":"5956_CR41","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.2337\/db10-1332","volume":"60","author":"N Mentis","year":"2011","unstructured":"Mentis N, Vardarli I, K\u00f6the LD et al (2011) GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60:1270\u20131276. https:\/\/doi.org\/10.2337\/db10-1332","journal-title":"Diabetes"},{"key":"5956_CR42","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.2337\/db20-0998","volume":"70","author":"JI Bagger","year":"2021","unstructured":"Bagger JI, Grondahl MFG, Lund A, Holst JJ, Vilsboll T, Knop FK (2021) Glucagonostatic potency of GLP-1 in patients with type 2 diabetes, patients with type 1 diabetes, and healthy control subjects. Diabetes 70:1347\u20131356. https:\/\/doi.org\/10.2337\/db20-0998","journal-title":"Diabetes"},{"key":"5956_CR43","doi-asserted-by":"publisher","first-page":"E 1038","DOI":"10.1152\/ajpendo.00665.2010","volume":"300","author":"A Lund","year":"2011","unstructured":"Lund A, Vilsb\u00f8ll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol (Endocrinol Metab) 300:E 1038\u20131046. https:\/\/doi.org\/10.1152\/ajpendo.00665.2010","journal-title":"Am J Physiol (Endocrinol Metab)"},{"issue":"1","key":"5956_CR44","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1210\/jcem.81.1.8550773","volume":"81","author":"B Willms","year":"1996","unstructured":"Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7\u201336) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81(1):327\u2013332. https:\/\/doi.org\/10.1210\/jcem.81.1.8550773","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR45","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1210\/jc.2003-030049","volume":"88","author":"JJ Meier","year":"2003","unstructured":"Meier JJ, Gallwitz B, Salmen S et al (2003) Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719\u20132725. https:\/\/doi.org\/10.1210\/jc.2003-030049","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR46","doi-asserted-by":"publisher","first-page":"E 621","DOI":"10.1152\/ajpendo.00499.2003","volume":"286","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Goetze O, Anstipp J et al (2004) Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol (Endocrinol Metab) 286:E 621-625. https:\/\/doi.org\/10.1152\/ajpendo.00499.2003","journal-title":"Am J Physiol (Endocrinol Metab)"},{"key":"5956_CR47","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2337\/db10-0474","volume":"60","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Kemmeries G, Holst JJ, Meier JJ (2011) Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 60:1561\u20131565. https:\/\/doi.org\/10.2337\/db10-0474","journal-title":"Diabetes"},{"key":"5956_CR48","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.2337\/dc14-1984","volume":"38","author":"JJ Meier","year":"2015","unstructured":"Meier JJ, Rosenstock J, Hincelin-Mery A et al (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: A randomized, open-label trial. Diabetes Care 38:1263\u20131273. https:\/\/doi.org\/10.2337\/dc14-1984","journal-title":"Diabetes Care"},{"key":"5956_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/EJE-21-0135","volume":"185","author":"S Stensen","year":"2021","unstructured":"Stensen S, Gasbjerg LS, Krogh LL et al (2021) Effects of endogenous GIP in patients with type 2 diabetes. Eur J Endocrinol 185:33\u201345. https:\/\/doi.org\/10.1530\/EJE-21-0135","journal-title":"Eur J Endocrinol"},{"key":"5956_CR50","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1038\/srep10202","volume":"5","author":"X Song","year":"2015","unstructured":"Song X, Jia H, Jiang Y et al (2015) Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: A meta-analysis. Sci Rep 5:10202. https:\/\/doi.org\/10.1038\/srep10202","journal-title":"Sci Rep"},{"key":"5956_CR51","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","volume":"41","author":"A Nahmias","year":"2021","unstructured":"Nahmias A, Stahel P, Tian L, Xiao C, Lewis GF (2021) GLP-1 (glucagon-like peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role. Arterioscler Thromb Vasc Biol 41:1893\u20131900. https:\/\/doi.org\/10.1161\/ATVBAHA.121.316311","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5956_CR52","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","volume":"53","author":"J Hsieh","year":"2010","unstructured":"Hsieh J, Longuet C, Baker CL et al (2010) The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53:552\u2013561. https:\/\/doi.org\/10.1007\/s00125-009-1611-5","journal-title":"Diabetologia"},{"key":"5956_CR53","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00125-006-0340-2","volume":"49","author":"N Matikainen","year":"2006","unstructured":"Matikainen N, Manttari S, Schweizer A et al (2006) Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 49:2049\u20132057. https:\/\/doi.org\/10.1007\/s00125-006-0340-2","journal-title":"Diabetologia"},{"key":"5956_CR54","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/dom.12359","volume":"16","author":"AJ Tremblay","year":"2014","unstructured":"Tremblay AJ, Lamarche B, Kelly I et al (2014) Effect of sitagliptin therapy on triglyceride-rich lipoprotein kinetics in patients with type 2 diabetes. Diabetes Obes Metab 16:1223\u20131229. https:\/\/doi.org\/10.1111\/dom.12359","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR55","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11883-022-00982-3","volume":"24","author":"P Novodvorsky","year":"2022","unstructured":"Novodvorsky P, Haluzik M (2022) The effect of GLP-1 receptor agonists on postprandial lipaemia. Curr Atheroscler Rep 24:13\u201321. https:\/\/doi.org\/10.1007\/s11883-022-00982-3","journal-title":"Curr Atheroscler Rep"},{"key":"5956_CR56","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2010.04.024","volume":"212","author":"MC Bunck","year":"2010","unstructured":"Bunck MC, Corner A, Eliasson B et al (2010) One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis 212:223\u2013229. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.04.024","journal-title":"Atherosclerosis"},{"key":"5956_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/dom.13487","volume":"21","author":"N Matikainen","year":"2019","unstructured":"Matikainen N, Soderlund S, Bjornson E et al (2019) Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab 21:84\u201394. https:\/\/doi.org\/10.1111\/dom.13487","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR58","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1210\/jc.2018-01176","volume":"104","author":"MB Whyte","year":"2019","unstructured":"Whyte MB, Shojaee-Moradie F, Sharaf SE et al (2019) Lixisenatide reduces chylomicron triacylglycerol by increased clearance. J Clin Endocrinol Metab 104:359\u2013368. https:\/\/doi.org\/10.1210\/jc.2018-01176","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR59","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1111\/jdi.13598","volume":"12","author":"H Kuwata","year":"2021","unstructured":"Kuwata H, Yabe D, Murotani K et al (2021) Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study. J Diabetes Investig 12:2162\u20132171. https:\/\/doi.org\/10.1111\/jdi.13598","journal-title":"J Diabetes Investig"},{"key":"5956_CR60","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2337\/diab.46.5.792","volume":"46","author":"WG Ding","year":"1997","unstructured":"Ding WG, Renstr\u00f6m E, Rorsman P, Buschard K, Gromada J (1997) Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46:792\u2013800. https:\/\/doi.org\/10.2337\/diab.46.5.792","journal-title":"Diabetes"},{"key":"5956_CR61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1096\/fj.02-0243fje","volume":"17","author":"FC Lynn","year":"2003","unstructured":"Lynn FC, Thompson SA, Pospisilik JA et al (2003) A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. FASEB J 17:91\u201393. https:\/\/doi.org\/10.1096\/fj.02-0243fje","journal-title":"FASEB J"},{"key":"5956_CR62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2337\/db06-1033","volume":"56","author":"G Xu","year":"2007","unstructured":"Xu G, Kaneto H, Laybutt DR et al (2007) Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56:1551\u20131558. https:\/\/doi.org\/10.2337\/db06-1033","journal-title":"Diabetes"},{"key":"5956_CR63","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00125-008-0943-x","volume":"51","author":"PV H\u00f8jberg","year":"2008","unstructured":"H\u00f8jberg PV, Zander M, Vilsb\u00f8ll T et al (2008) Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 51:632\u2013640. https:\/\/doi.org\/10.1007\/s00125-008-0943-x","journal-title":"Diabetologia"},{"key":"5956_CR64","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1172\/JCI140046","volume":"130","author":"OS Oduori","year":"2020","unstructured":"Oduori OS, Murao N, Shimomura K et al (2020) Gs\/Gq signaling switch in beta cells defines incretin effectiveness in diabetes. J Clin Invest 130:6639\u20136655. https:\/\/doi.org\/10.1172\/JCI140046","journal-title":"J Clin Invest"},{"key":"5956_CR65","doi-asserted-by":"publisher","first-page":"E 304","DOI":"10.1152\/ajpendo.1985.248.3.E304","volume":"248","author":"T Ikeda","year":"1985","unstructured":"Ikeda T, Mokuda O, Kuno S, Tokumori Y, Tominaga M, Mashiba H (1985) Enhanced intestinal insulinotropic effect in streptozotocin-diabetic rats. Am J Physiol 248:E 304-308. https:\/\/doi.org\/10.1152\/ajpendo.1985.248.3.E304","journal-title":"Am J Physiol"},{"key":"5956_CR66","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/psc.861","volume":"13","author":"N Irwin","year":"2007","unstructured":"Irwin N, McClean PL, Flatt PR (2007) Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob\/ob) mice. J Pept Sci 13:400\u2013405. https:\/\/doi.org\/10.1002\/psc.861","journal-title":"J Pept Sci"},{"key":"5956_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mce.2015.11.019","volume":"420","author":"PJ Millar","year":"2016","unstructured":"Millar PJ, Pathak V, Moffett RC et al (2016) Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice. Mol Cell Endocrinol 420:37\u201345. https:\/\/doi.org\/10.1016\/j.mce.2015.11.019","journal-title":"Mol Cell Endocrinol"},{"key":"5956_CR68","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2337\/db18-1123","volume":"68","author":"LS Gasbjerg","year":"2019","unstructured":"Gasbjerg LS, Helsted MM, Hartmann B et al (2019) Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals. Diabetes 68:906\u2013917. https:\/\/doi.org\/10.2337\/db18-1123","journal-title":"Diabetes"},{"key":"5956_CR69","doi-asserted-by":"publisher","first-page":"170183","DOI":"10.1016\/j.peptides.2019.170183","volume":"125","author":"LS Gasbjerg","year":"2020","unstructured":"Gasbjerg LS, Bergmann NC, Stensen S et al (2020) Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides 125:170183. https:\/\/doi.org\/10.1016\/j.peptides.2019.170183","journal-title":"Peptides"},{"key":"5956_CR70","doi-asserted-by":"publisher","first-page":"dgz175","DOI":"10.1210\/clinem\/dgz175","volume":"105","author":"LS Gasbjerg","year":"2020","unstructured":"Gasbjerg LS, Helsted MM, Hartmann B et al (2020) GIP and GLP-1 receptor antagonism during a meal in healthy individuals. J Clin Endocrinol Metab 105:dgz175. https:\/\/doi.org\/10.1210\/clinem\/dgz175","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR71","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.2337\/db07-0100","volume":"56","author":"FK Knop","year":"2007","unstructured":"Knop FK, Vilsb\u00f8ll T, H\u00f8jberg PV et al (2007) Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951\u20131959. https:\/\/doi.org\/10.2337\/db07-0100","journal-title":"Diabetes"},{"key":"5956_CR72","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1210\/jc.2010-2178","volume":"96","author":"I Vardarli","year":"2011","unstructured":"Vardarli I, Nauck MA, K\u00f6the LD et al (2011) Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as \u201cisoglycemic\u201d intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 96:945\u2013954. https:\/\/doi.org\/10.1210\/jc.2010-2178","journal-title":"J Clin Endocrinol Metab"},{"key":"5956_CR73","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2337\/db13-0805","volume":"63","author":"I Vardarli","year":"2014","unstructured":"Vardarli I, Arndt E, Deacon CF, Holst JJ, Nauck MA (2014) Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and \u201cisoglycemic\u201d intravenous glucose. Diabetes 63:663\u2013674. https:\/\/doi.org\/10.2337\/db13-0805","journal-title":"Diabetes"},{"key":"5956_CR74","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2337\/dc06-1549","volume":"30","author":"B Laferrere","year":"2007","unstructured":"Laferrere B, Heshka S, Wang K et al (2007) Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care 30:1709\u20131716. https:\/\/doi.org\/10.2337\/dc06-1549","journal-title":"Diabetes Care"},{"key":"5956_CR75","doi-asserted-by":"publisher","first-page":"E 774","DOI":"10.1152\/ajpendo.00496.2015","volume":"310","author":"BA Aulinger","year":"2016","unstructured":"Aulinger BA, Vahl TP, Prigeon RL, D\u2019Alessio DA, Elder DA (2016) The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact? Am J Physiol (Endocrinol Metab) 310:E 774-781. https:\/\/doi.org\/10.1152\/ajpendo.00496.2015","journal-title":"Am J Physiol (Endocrinol Metab)"},{"key":"5956_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","volume":"13","author":"CF Deacon","year":"2011","unstructured":"Deacon CF (2011) Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 13:7\u201318. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01306.x","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR77","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","volume":"22","author":"R Eissele","year":"1992","unstructured":"Eissele R, G\u00f6ke R, Willemer S et al (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22:283\u2013291. https:\/\/doi.org\/10.1111\/j.1365-2362.1992.tb01464.x","journal-title":"Eur J Clin Invest"},{"key":"5956_CR78","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.celrep.2016.03.091","volume":"15","author":"RD Ramracheya","year":"2016","unstructured":"Ramracheya RD, McCulloch LJ, Clark A et al (2016) PYY-dependent restoration of impaired insulin and glucagon secretion in type 2 diabetes following Roux-en-Y gastric bypass surgery. Cell Rep 15:944\u2013950. https:\/\/doi.org\/10.1016\/j.celrep.2016.03.091","journal-title":"Cell Rep"},{"key":"5956_CR79","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cen.12167","volume":"80","author":"TJ Oh","year":"2014","unstructured":"Oh TJ, Kim MY, Shin JY et al (2014) The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes. Clin Endocrinol (Oxf) 80:221\u2013227. https:\/\/doi.org\/10.1111\/cen.12167","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"5956_CR80","doi-asserted-by":"publisher","first-page":"e000352","DOI":"10.1136\/bmjdrc-2016-000352","volume":"5","author":"TP Yeow","year":"2017","unstructured":"Yeow TP, Pacini G, Tura A et al (2017) Preserved glucagon-like peptide-1 responses to oral glucose, but reduced incretin effect, insulin secretion and sensitivity in young Asians with type 2 diabetes mellitus. BMJ Open Diabetes Res Care 5(1):e000352. https:\/\/doi.org\/10.1136\/bmjdrc-2016-000352","journal-title":"BMJ Open Diabetes Res Care"},{"key":"5956_CR81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","volume":"46","author":"SE Kahn","year":"2003","unstructured":"Kahn SE (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46:3\u201319. https:\/\/doi.org\/10.1007\/s00125-002-1009-0","journal-title":"Diabetologia"},{"issue":"3","key":"5956_CR82","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365528509091656","volume":"20","author":"PF Amland","year":"1985","unstructured":"Amland PF, Jorde R, Burhol PG, Giercksky KE (1985) Effect of intravenously infused porcine GIP on serum insulin in obese and lean subjects studied with the hyperglycemic clamp technique. Scand J Gastroenterol 20(3):309\u2013314. https:\/\/doi.org\/10.3109\/00365528509091656","journal-title":"Scand J Gastroenterol"},{"key":"5956_CR83","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA (2022) Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol 21:169. https:\/\/doi.org\/10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"5956_CR84","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Frias","year":"2021","unstructured":"Frias JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385:503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"5956_CR85","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nm727","volume":"8","author":"K Miyawaki","year":"2002","unstructured":"Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738\u2013742. https:\/\/doi.org\/10.1038\/nm727","journal-title":"Nat Med"},{"issue":"3","key":"5956_CR86","doi-asserted-by":"publisher","first-page":"e13073","DOI":"10.14814\/phy2.13073","volume":"5","author":"A Asmar","year":"2017","unstructured":"Asmar A, Asmar M, Simonsen L et al (2017) Glucagon-like peptide-1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men. Physiol Rep 5(3):e13073. https:\/\/doi.org\/10.14814\/phy2.13073","journal-title":"Physiol Rep"},{"key":"5956_CR87","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW (2020) How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab 31:410\u2013421. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006","journal-title":"Trends Endocrinol Metab"},{"key":"5956_CR88","doi-asserted-by":"publisher","first-page":"209ra151","DOI":"10.1126\/scitranslmed.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan B, Ma T, Ottaway N et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151. https:\/\/doi.org\/10.1126\/scitranslmed.3007218","journal-title":"Sci Transl Med"},{"key":"5956_CR89","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.2337\/db21-0459","volume":"70","author":"T Borner","year":"2021","unstructured":"Borner T, Geisler CE, Fortin SM et al (2021) GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes 70:2545\u20132553. https:\/\/doi.org\/10.2337\/db21-0459","journal-title":"Diabetes"},{"key":"5956_CR90","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","volume":"33","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Delessa CT, Augustin R et al (2021) The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab 33:833\u2013844. https:\/\/doi.org\/10.1016\/j.cmet.2021.01.015","journal-title":"Cell Metab"},{"key":"5956_CR91","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","volume":"30","author":"AE Adriaenssens","year":"2019","unstructured":"Adriaenssens AE, Biggs EK, Darwish T et al (2019) Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab 30:987\u2013996. https:\/\/doi.org\/10.1016\/j.cmet.2019.07.013","journal-title":"Cell Metab"},{"key":"5956_CR92","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","volume":"62","author":"NC Bergmann","year":"2019","unstructured":"Bergmann NC, Lund A, Gasbjerg LS et al (2019) Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study. Diabetologia 62:665\u2013675. https:\/\/doi.org\/10.1007\/s00125-018-4810-0","journal-title":"Diabetologia"},{"key":"5956_CR93","doi-asserted-by":"publisher","first-page":"E614","DOI":"10.1152\/ajpendo.00639.2009","volume":"298","author":"M Asmar","year":"2010","unstructured":"Asmar M, Tangaa W, Madsbad S et al (2010) On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab 298:E614-621. https:\/\/doi.org\/10.1152\/ajpendo.00639.2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5956_CR94","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","volume":"10","author":"T Heise","year":"2022","unstructured":"Heise T, Mari A, DeVries JH et al (2022) Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 10:418\u2013429. https:\/\/doi.org\/10.1016\/S2213-8587(22)00085-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"5956_CR95","doi-asserted-by":"publisher","first-page":"e146353","DOI":"10.1172\/JCI146353","volume":"131","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, Christe ME, Collins KA et al (2021) GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest 131:e146353. https:\/\/doi.org\/10.1172\/JCI146353","journal-title":"J Clin Invest"},{"issue":"10","key":"5956_CR96","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/dom.14110","volume":"22","author":"S Urva","year":"2020","unstructured":"Urva S, Coskun T, Loghin C et al (2020) The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 22(10):1886\u20131891. https:\/\/doi.org\/10.1111\/dom.14110","journal-title":"Diabetes Obes Metab"},{"key":"5956_CR97","doi-asserted-by":"publisher","first-page":"bnz002","DOI":"10.1210\/endrev\/bnz002","volume":"41","author":"EA Killion","year":"2020","unstructured":"Killion EA, Lu SC, Fort M, Yamada Y, Veniant MM, Lloyd DJ (2020) Glucose-dependent insulinotropic polypeptide receptor therapies for the treatment of obesity, do agonists = antagonists? Endocr Rev 41:bnz002. https:\/\/doi.org\/10.1210\/endrev\/bnz002","journal-title":"Endocr Rev"},{"key":"5956_CR98","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.molmet.2020.101139","volume":"46","author":"JE Campbell","year":"2020","unstructured":"Campbell JE (2020) Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. Mol Metab 46:101139. https:\/\/doi.org\/10.1016\/j.molmet.2020.101139","journal-title":"Mol Metab"},{"key":"5956_CR99","doi-asserted-by":"publisher","first-page":"eaat3392","DOI":"10.1126\/scitranslmed.aat3392","volume":"10","author":"EA Killion","year":"2018","unstructured":"Killion EA, Wang J, Yie J et al (2018) Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci Transl Med 10:eaat3392. https:\/\/doi.org\/10.1126\/scitranslmed.aat3392","journal-title":"Sci Transl Med"},{"key":"5956_CR100","unstructured":"Amgen (2022) AMG 133 is a first-in-class investigational bispecific molecule that activates GLP-1R and inhibits GIPR; phase 1 results showed up to 14.5% reduction in body weight at the highest dose after 12 weeks. https:\/\/www.amgen.com\/newsroom\/press-releases\/2022\/12\/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022"},{"key":"5956_CR101","doi-asserted-by":"publisher","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","volume":"105","author":"JJ Holst","year":"2020","unstructured":"Holst JJ, Rosenkilde MM (2020) GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists. J Clin Endocrinol Metab 105:e2710\u2013e2716. https:\/\/doi.org\/10.1210\/clinem\/dgaa327","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"5956_CR102","doi-asserted-by":"publisher","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","volume":"5","author":"FS Willard","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB et al (2020) Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 5(17):e140532. https:\/\/doi.org\/10.1172\/jci.insight.140532","journal-title":"JCI Insight"},{"key":"5956_CR103","doi-asserted-by":"publisher","first-page":"101181","DOI":"10.1016\/j.molmet.2021.101181","volume":"49","author":"A Novikoff","year":"2021","unstructured":"Novikoff A, O\u2019Brien SL, Bernecker M et al (2021) Spatiotemporal GLP-1 and GIP receptor signaling and trafficking\/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab 49:101181. https:\/\/doi.org\/10.1016\/j.molmet.2021.101181","journal-title":"Mol Metab"},{"key":"5956_CR104","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","volume":"9","author":"B Jones","year":"2018","unstructured":"Jones B, Buenaventura T, Kanda N et al (2018) Targeting GLP-1 receptor trafficking to improve agonist efficacy. Nat Commun 9:1602. https:\/\/doi.org\/10.1038\/s41467-018-03941-2","journal-title":"Nat Commun"},{"key":"5956_CR105","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.2337\/dbi21-0026","volume":"70","author":"JJ Holst","year":"2021","unstructured":"Holst JJ (2021) Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 Banting Medal for Scientific Achievement Award Lecture. Diabetes 70:2468\u20132475. https:\/\/doi.org\/10.2337\/dbi21-0026","journal-title":"Diabetes"},{"issue":"10366","key":"5956_CR106","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400(10366):1869\u20131881. https:\/\/doi.org\/10.1016\/S0140-6736(22)02033-5","journal-title":"Lancet"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-05956-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05956-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T06:07:49Z","timestamp":1694758069000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-05956-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":106,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5956"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-05956-x","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"10 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We acknowledge help from Sonja Bartholom\u00e9 in retrieving literature.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data extracted from included studies; data used for all analyses and any other materials used in the review can be accessed on reasonable request and at the discretion of the authors by contacting the corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Open Access funding enabled and organized by Projekt DEAL. Work in TDM\u2019s laboratory is supported by the German Research Foundation (DFG TRR296, TRR152, SFB1123 and GRK 2816\/1), the German Center for Diabetes Research (DZD) and the European Research Council ERC-CoG Trusted (no.101044445).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MAN has been a member of the advisory boards of, or has consulted with, Boehringer Ingelheim, Eli Lilly, Medtronic, Merck Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Sun Pharma and Structure Therapeutics (ShouTi, Gasherbrum). He has received grant support from Merck Sharp & Dohme. He has also served on the speakers\u2019 bureau of Eli Lilly, Menarini\/Berlin Chemie, Merck Sharp & Dohme, Medscape, Medical Learning Institute and Novo Nordisk. TDM receives funding from Novo Nordisk and has received speaking fees within the last 3 years from Novo Nordisk, Eli Lilly, AstraZeneca and Berlin Chemie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"MAN and TDM designed the review and jointly searched the literature, designed the figures and tables and wrote the manuscript. Both authors approved the final draft of the manuscript and the decision to submit it for publication. The manuscript is in part based on the content of MAN's Claude Bernard Lecture presented on 20 September 2022 at the EASD Annual Meeting in Stockholm, Sweden. MAN takes full responsibility for the work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}